Sophiris Bio Inc. (NASDAQ:SPHS) shares traded up 7.6% during mid-day trading on Thursday . The company traded as high as $4.19 and last traded at $4.10, with a volume of 2,576,685 shares. The stock had previously closed at $3.81.

A number of research analysts recently issued reports on the company. Echelon Wealth Partners reaffirmed a “buy” rating and set a $5.00 target price on shares of Sophiris Bio in a report on Friday, June 10th. Maxim Group reaffirmed a “buy” rating and set a $4.00 target price on shares of Sophiris Bio in a report on Thursday, March 24th.

The stock’s market cap is $82.43 million. The stock has a 50-day moving average price of $2.07 and a 200-day moving average price of $1.68.

Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. On average, equities research analysts anticipate that Sophiris Bio Inc. will post ($0.73) EPS for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.